- DBV Technologies SA DBVT initiated the phase 3 VITESSE study with the modified Viaskin Peanut Patch in children aged 4 to 7 years with peanut allergies.
- DBV expects to enroll 600 subjects for participation in the VITESSE study, randomized 2:1 active to placebo. The first patient screened is expected in Q4 2022, the last patient screened by the end of 2023.
- The company expects to release top-line results in the first quarter of 2025.
- Also read: HC Wainwright Says Viaskin Benefit Confirmed in Toddlers…What’s Next?
- VITESSE is a double-blind, placebo-controlled, randomized phase 3 study to evaluate the efficacy and safety of patch immunotherapy with the modified Viaskin Peanut 250 µg patch in peanut-allergic children aged 4 to 7 years.
- The primary efficacy endpoint is the percentage of responders in the active versus placebo arms at 12 months.
- Price promotion: DBVT shares are up 1.56% to $2.29 on the latest check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
